CH-275

CH275 (osmotic pump administration; 56 μM; two weeks) decreases thelevel of neprilysin/SRIF in theAppknock-in mice^[3].CH275 directly injects into the Lacunosum molecular layer (Lmol) layer of 2-month-old App^NL-G-F mice for four months. App^NL-G-F mice begin to exhibit Aβ plaques at two months of age, but CH275 leads to robustly increased the expression of neprilysin in hippocampus which is paralleled by a clear reduction in Aβ plaque load in the same region, and without causing any toxic side effects^[3].